Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Juli 2021 08:15 ET | Quelle: Palisade Bio, Inc.

Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery

Statistically significant 1.1-day acceleration in return of bowel function Favorable overall safety profile in 120 patients CARLSBAD, Calif. and SHANGHAI, China, July 29, 2021 (GLOBE NEWSWIRE) --...
13. Juli 2021 08:00 ET | Quelle: Palisade Bio, Inc.

Palisade Bio Enters into Worldwide In-Licensing Agreement with University of California for Technology to Support Target Identification, Drug Discovery, and Clinical Development

CARLSBAD, Calif., July 13, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications,...
15. Juni 2021 08:15 ET | Quelle: Palisade Bio, Inc.

Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide Preparation for Late-Stage Clinical Trials of LB1148 in Accelerating Postoperative Return of Bowel Function and Reduction of Post-Surgical Adhesions

CARLSBAD, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications,...
13. Mai 2021 07:00 ET | Quelle: Palisade Bio, Inc.

Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery

LB1148 was previously granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of postoperative GI dysfunction associated with pediatric cardiovascular surgery...
19. Dezember 2018 02:04 ET | Quelle: Neuralstem, Inc.

Neuralstem Melantik Ken Carter, Ph.D., sebagai Pengerusi Eksekutif Lembaga Pengarah

GERMANTOWN, Md., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR), syarikat biofarmaseutikal yang memfokuskan pada perkembangan terapi sistem saraf berasaskan teknologi sel induk...
19. Dezember 2018 02:04 ET | Quelle: Neuralstem, Inc.

뉴럴스템, 총괄회장에 켄 카터 박사 임명

미국 메릴랜드주 저먼타운, Dec. 19, 2018 (GLOBE NEWSWIRE) -- 신경 줄기 세포 및 저분자 화합물 기술을 기반으로 신경계 치료제 개발에 주력하는 바이오 제약회사 뉴럴스템(Neuralstem) Nasdaq:CUR)이 켄 카터(Kenneth C. Carter) 박사를 총괄회장으로 선임했다. 카터 박사는 2019년 1월 1일부로...
19. Dezember 2018 02:04 ET | Quelle: Neuralstem, Inc.

ニューラルステム、ケン･カーター博士を取締役会の常務会長に任命

メリーランド州ジャーマンタウン発, Dec. 19, 2018 (GLOBE NEWSWIRE) -- 神経幹細胞および小分子テクノロジーを基盤とする神経系治療の開発を専門にしているバイオ医薬品会社、ニューラルステム (Neuralstem, Inc.、Nasdaq: CUR) は本日、ケン･C･カーター博士 (Kenneth C. Carter, Ph.D.)...
19. Dezember 2018 02:04 ET | Quelle: Neuralstem, Inc.

Neuralstem任命Ken Carter博士出任董事會執行主席

美國馬里蘭州日耳曼敦, Dec. 19, 2018 (GLOBE NEWSWIRE) -- 專注於根據神經幹細胞及小分子科技研發神經系統療法的生物製藥公司Neuralstem, Inc.（Nasdaq代碼：CUR）任命Kenneth C. Carter博士出任公司董事會的執行主席，自2019年1月1日起開始生效。Carter博士將接替即將卸任的臨時首席執政官Jim Scully。 ...
19. Dezember 2018 02:04 ET | Quelle: Neuralstem, Inc.

Neuralstem任命Ken Carter博士担任董事会执行主席

美国马里兰州日耳曼敦, Dec. 19, 2018 (GLOBE NEWSWIRE) -- 专注于根据其神经干细胞和小分子技术研发神经系统疗法的生物制药公司Neuralstem, Inc.（Nasdaq代码：CUR）任命Kenneth C. Carter博士担任公司董事会的执行主席，自2019年1月1日开始生效。Carter博士将接替即将卸任的临时首席执政官Jim Scully。 ...
18. Dezember 2018 07:00 ET | Quelle: Neuralstem, Inc.

Neuralstem Appoints Ken Carter, Ph.D., as Executive Chairman of the Board

GERMANTOWN, Md., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell...

Vorherige Seite

Nächste Seite